Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16

Benzinga Newsdesk www.benzinga.com Positive 91.5%

Neg 0% Neu 0% Pos 91.5%

Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.